News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
447,442 Results
Type
Article (29042)
Company Profile (160)
Press Release (418240)
Section
Business (139371)
Career Advice (1543)
Deals (24041)
Drug Delivery (73)
Drug Development (49443)
Employer Resources (154)
FDA (9948)
Job Trends (10664)
News (225289)
Policy (18651)
Tag
Academia (2048)
Africa (566)
Alliances (32932)
Alzheimer's disease (788)
Antibody-drug conjugate (ADC) (44)
Approvals (9903)
Arizona (93)
Artificial intelligence (57)
Asia (24303)
Australia (4039)
Bankruptcy (170)
Best Places to Work (8371)
Biosimilars (44)
Biotechnology (101)
C2C Services and Suppliers (46147)
California (1071)
Canada (657)
Cancer (233)
Career advice (1340)
Cell therapy (80)
China (67)
Clinical research (38548)
Collaboration (85)
Connecticut (45)
COVID-19 (1459)
Cystic fibrosis (57)
Data (100)
Diabetes (44)
Diagnostics (4091)
Drug pricing (47)
Earnings (52099)
Employer resources (131)
Europe (57148)
Events (70182)
Executive appointments (79)
FDA (10064)
Florida (138)
Funding (59)
Gene therapy (52)
GLP-1 (368)
Government (2455)
Healthcare (12663)
Hotbed/Location (311828)
Illinois (155)
Indiana (125)
Infectious disease (1475)
Inflammatory bowel disease (78)
Interviews (226)
IPO (11384)
Job creations (2345)
Job search strategy (1189)
Kansas (56)
Layoffs (230)
Legal (4201)
Lung cancer (58)
Management (47)
Manufacturing (48)
Maryland (192)
Massachusetts (901)
Medical device (8419)
Medtech (8422)
Mergers & acquisitions (12601)
Metabolic disorders (153)
Michigan (80)
Minnesota (142)
Neuroscience (878)
New Jersey (354)
New York (375)
NextGen Class of 2024 (4562)
Non-profit (3673)
North Carolina (454)
Northern California (521)
Obesity (105)
Ohio (73)
Opinion (118)
Pennsylvania (302)
People (43499)
Pharmaceutical (41)
Phase I (11266)
Phase II (16813)
Phase III (13853)
Pipeline (79)
Postmarket research (1559)
Preclinical (4839)
Press Release (71)
Rare diseases (91)
Real estate (4193)
Recruiting (59)
Regulatory (12511)
Reports (42)
Research institute (1807)
Resumes & cover letters (211)
South America (775)
Southern California (432)
Startups (2750)
Texas (129)
United States (5061)
Vaccines (216)
Washington State (101)
Weight loss (90)
Date
Last 7 days (322)
Last 30 days (1582)
Last 365 days (27382)
2024 (17935)
2023 (29315)
2022 (37232)
2021 (40836)
2020 (38210)
2019 (32391)
2018 (24297)
2017 (22281)
2016 (21359)
2015 (25028)
2014 (19126)
2013 (15448)
2012 (16562)
2011 (17130)
2010 (16317)
447,442 Results for "anavex life sciences corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Anavex Life Sciences Announces Expansion of Leadership Team
Anavex Life Sciences Corp. announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market.
May 22, 2024
·
6 min read
Pharm Country
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.
June 20, 2024
·
3 min read
Pharm Country
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.
May 14, 2024
·
3 min read
Business
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024.
May 2, 2024
·
3 min read
Pharm Country
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference.
March 25, 2024
·
3 min read
Business
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system diseases, reported financial results for its fiscal quarter ended March 31, 2024.
May 9, 2024
·
11 min read
Drug Development
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.
March 18, 2024
·
8 min read
Pharm Country
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system diseases, announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.
April 11, 2024
·
3 min read
Pharm Country
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Anavex Life Sciences Corp. today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024.
February 26, 2024
·
3 min read
Pharm Country
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
Anavex Life Sciences Corp. today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in-human study which achieved its safety objectives.
January 24, 2024
·
5 min read
1 of 44,745
Next